In vitro and in vivo application of sub-atmospheric, negative pressure on growth factor starting material, such as whole blood, extracts growth factors from the platelet granules of the growth factor starting material in a non-destructive medium without activating the clotting process. The extracted growth factors are released into a growth factor composition containing blood plasma, extracellular fluid or interstitial fluid depending upon the type and location of the growth factor starting material. The growth factors have a weight of about 70-76 kDaltons and are applied in either a filtered or unfiltered state topically to the area of a surface wound to effect healing. The extracted growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by lyophilization. Then at a later date, the freeze-dried product is reconstituted by normal saline for treatment of a patient's wound, for use in a surgical procedure, or for tissue regeneration.

Disclosed is a stem cell generator for the generation of organoids after the development of biological materials loaded with active substances which are implanted into an animal or a human body. The active substances are mesenchymal stem cells, bone morphogenetic protein-2 or bone morphogenesis protein-7, other growth factors/polypeptides or growth factors/polypeptide combinations having the ability of inducing bone regeneration, or combinations thereof. The stem cell generator contains various types of blood cells and hematopoietic progenitor/stem cells having complete functions. The produced stem cells are used for treating hematopoietic damage, and can treat bone marrow failure and leukemia caused by radiotherapy/chemotherapy.

Disclosed is a new use of a stem cell generator in preparation of bone defect repair materials, wherein the stem cell generator is formed by implanting a biomaterial with osteogenic induction capability or a biomaterial loaded with active substances and/or cells into an animal or a human body and generating organoids after development, the active substances are bone morphogenetic protein-2, or bone morphogenetic protein-7, other growth factors/polypeptides having bone regeneration induction ability, growth factors/polypeptide combinations, or a combination thereof. The cells are bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells or other derived mesenchymal stem cells; other types of cells with osteogenic differentiation capability; cells that aid in osteogenic differentiation of mesenchymal stem cells, such as vascular endothelial cells and the like. The stem cell generator is used to prepare bone repair materials for treatment of various types of bone defects or bone deformities that are spontaneous or caused by trauma.

Compositions and methods of using same for tissue regeneration are provided. Accordingly, there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and Copolymer 1 at a concentration range of 10-150 microgram/ml. Also provided is a composition comprising a hyaluronic acid, a laminin polypeptide and vitamin E at a concentration range of 0.3-30 mM. Also provided are matrices and hydrogels of the compositions and methods of using same.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

Luminal grafts and methods of making and using the same. An exemplary luminal graft of the present disclosure is configured as a generally tubular element configured for nerve cells to grow therethrough and comprises at least one sheet of biological tissue having elastin fibers and collagen fibers, with the elastin fibers being a dominant component thereof; and a plurality of microchannels formed on a surface of the at least one sheet of biological tissue, each of the microchannels extending longitudinally between a first end and a second end of the at least one sheet of biological tissue and configured to provide intraluminal structural guidance to nerve cells proliferating therethrough.

Provided herein are human arterial endothelial cell-seeded polymeric vascular grafts suitable for replacing or bypassing natural blood vessels and exhibiting increased long term patency rates and reduced leukocyte adhesion relative to grafts comprising venous endothelial cells. Methods for generating the human arterial endothelial cell-seeded vascular grafts and therapeutic uses of the same are also described.

A composition includes a dual crosslinkable hydrogel that includes a plurality of polymer macromers, which are crosslinked with a first agent and a second agent different than the first agent, wherein the crosslinks formed using the second agent are reversible and repeatable to allow the mechanical properties of the hydrogel to be dynamically adjusted.

The present invention pertains to methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby. The coating solution described herein comprises one or more antimicrobial peptides (AMPs) dissolved in a buffer containing an anionic surfactant, wherein the AMPs are amphipathic and cationic.

Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.